Microbix Reports Results for Fiscal 2020
Retrieved on:
Friday, December 18, 2020
MISSISSAUGA, Ontario, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, Microbix), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, reports results for its 2020 fiscal year (2020) and fourth quarter (Q4) ended September 30, 2020, with continued progress toward its operational goals.
Key Points:
- MISSISSAUGA, Ontario, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, Microbix), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, reports results for its 2020 fiscal year (2020) and fourth quarter (Q4) ended September 30, 2020, with continued progress toward its operational goals.
- 2020 did not achieve the financial targets we had set-out at the start of the year due in large part to the COVID-19 pandemic.
- This occurred principally in fiscal Q3, the first-ever quarter of constant usage of all bioreactor units, and had a large negative impact on margin and bottom-line results that quarter.
- Similarly, due to Microbix not achieving its operational profitability goals in 2020, a write-down of Deferred Tax Assets (DTAs) was also taken.